Publications by authors named "A Sanjuanbenito"
Background And Aims: Timely and accurate detection of tumor recurrence in pancreatic ductal adenocarcinoma (PDAC) patients is an urgent and unmet medical need. This study aimed to develop a noninvasive molecular diagnostic procedure for the detection of recurrence after PDAC resection based on quantification of circulating mRNA and miRNA biomarkers in serum samples.
Methods: In a multicentric study, serum samples from a total of 146 patients were prospectively collected after resection.
The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no known pathogenic germline variants.
Fam Cancer
August 2024
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the Western world. The number of diagnosed cases and the mortality rate are almost equal as the majority of patients present with advanced disease at diagnosis. Between 4 and 10% of pancreatic cancer cases have an apparent hereditary background, known as hereditary pancreatic cancer (HPC) and familial pancreatic cancer (FPC), when the genetic basis is unknown.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on pancreatic ductal adenocarcinoma (PDAC) and how cancer stem cells (CSCs) contribute to its aggressive nature and resistance to therapies, particularly immune checkpoint inhibitors.
- Researchers used a mouse model and primary tumor cell lines to identify CSC populations and their immune evasion strategies, discovering that the gene peptidoglycan recognition protein 1 (PGLYRP1) is significantly overexpressed in these cells.
- The findings suggest PGLYRP1 plays a key role in helping CSCs evade immune responses, highlighting its potential as a new target for immunotherapy in PDAC patients.
The Spanish Familial Pancreatic Cancer Registry (PANGENFAM) was established in 2009 and aims to characterize the genotype and phenotype of familial pancreatic cancer (FPC). Furthermore, an early detection screening program for pancreatic ductal adenocarcinoma (PDAC) is provided to healthy high-risk individuals from FPC and hereditary pancreatic cancer families (first-degree relatives). This article describes our experience over the last 10 years in high-risk screening.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the recurrence of isolated pancreatic metastases from Renal Cell Carcinoma (RCC) and evaluates the outcomes of repeat pancreatic resections after initial surgery.
- It involved a retrospective analysis of 131 resections in 116 patients from January 2010 to May 2020, comparing those who had single versus iterative pancreatic surgeries.
- Results indicated that while disease-free survival (DFS) rates were slightly better in the iterative group, overall survival (OS) rates were similar for both groups, suggesting that repeat surgery is a viable option for managing RCC-related pancreatic metastases.